1. Home
  2. LEGN vs GATX Comparison

LEGN vs GATX Comparison

Compare LEGN & GATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • GATX
  • Stock Information
  • Founded
  • LEGN 2014
  • GATX 1898
  • Country
  • LEGN United States
  • GATX United States
  • Employees
  • LEGN N/A
  • GATX N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • GATX Transportation Services
  • Sector
  • LEGN Health Care
  • GATX Consumer Discretionary
  • Exchange
  • LEGN Nasdaq
  • GATX Nasdaq
  • Market Cap
  • LEGN 5.4B
  • GATX 5.5B
  • IPO Year
  • LEGN 2020
  • GATX N/A
  • Fundamental
  • Price
  • LEGN $38.96
  • GATX $158.49
  • Analyst Decision
  • LEGN Strong Buy
  • GATX Buy
  • Analyst Count
  • LEGN 12
  • GATX 2
  • Target Price
  • LEGN $73.91
  • GATX $172.50
  • AVG Volume (30 Days)
  • LEGN 1.6M
  • GATX 161.8K
  • Earning Date
  • LEGN 08-08-2025
  • GATX 07-29-2025
  • Dividend Yield
  • LEGN N/A
  • GATX 1.54%
  • EPS Growth
  • LEGN N/A
  • GATX 12.52
  • EPS
  • LEGN N/A
  • GATX 7.90
  • Revenue
  • LEGN $728,303,000.00
  • GATX $1,627,200,000.00
  • Revenue This Year
  • LEGN $65.49
  • GATX $10.94
  • Revenue Next Year
  • LEGN $53.76
  • GATX $5.40
  • P/E Ratio
  • LEGN N/A
  • GATX $20.04
  • Revenue Growth
  • LEGN 112.46
  • GATX 12.07
  • 52 Week Low
  • LEGN $27.34
  • GATX $127.70
  • 52 Week High
  • LEGN $60.87
  • GATX $168.89
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 66.26
  • GATX 56.21
  • Support Level
  • LEGN $34.64
  • GATX $157.10
  • Resistance Level
  • LEGN $39.88
  • GATX $161.03
  • Average True Range (ATR)
  • LEGN 1.46
  • GATX 2.63
  • MACD
  • LEGN 0.37
  • GATX 0.17
  • Stochastic Oscillator
  • LEGN 87.67
  • GATX 67.17

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About GATX GATX Corporation

GATX Corp is a provider of railcar leasing and maintenance services. GATX operates in business segments including rail North America, rail international, Engine Leasing, and others. The rail business offers railcar leasing and maintenance, as well as asset-related, financial, and management services. The company owns and leases fleets in North America, Europe, and Asia, which consist of tank and freight railcars. Industries served include refining and petroleum, chemicals and plastics, railroads and other transportation, mining, and food and agriculture.

Share on Social Networks: